. Author manuscript; available in PMC: 2010 Nov 15.

Published in final edited form as: Clin Infect Dis. 2009 Nov 15;49(10):1570–1578. doi: 10.1086/644772

Table 1. Baseline input parameters for a simulation study of the years of life lost due to suboptimal HIV care in the United States.

Variable			Baseline input		Source
Age at seroconversion, mean years (SD)			33.0 (7.5)		Multicenter AIDS Cohort Study [23]
HIV RNA, mean log₁₀ copies/ml (SD)			4.8 (0.6)		Staszewski, et al. [63]
CD4 count, mean cells/μl (SD) ^†			534 (164)		Walensky, et al. [33]
Antiretroviral regimens		% suppressed at 48 weeks		CD4 increase at 48 weeks (cells/μl)	Source
1. Efavirenz + tenofovir DF + emtricitabine		84		190	Gallant, et al. [64]
2. Atazanavir/ritonavir + 2 NRTIs		71		110	Johnson, et al. [29]
3. Regimen 3^*		66		121	Johnson, et al. [29]
4. Regimen 4^*		65 (24 weeks)		102 (24 weeks)	Grinsztejn, et al. [65]
5. Regimen 5^*		40 (24 weeks)		121	Nelson, et al. [31] Lalezari, et al. [66]
Discontinuation rates for ART		White	Black	Hispanic
Women		5%	10%	14%	Anastos, et al. [3] Ahdieh-Grant, et al. [37]
Men		5%	5%	5%	Li, et al. [9]
Variable		Baseline input

			CD4 count at ART initiation (%) ^‡

Subgroup		Percent of cohort (%)	≥ 200 cells/μl	50 – 199 cells/μl	< 50 cells/μl

Overall	Total	100.0	57.9	22.6	19.5
	Women	25.0	62.9	20.2	16.9
	Men	75.0	56.3	23.4	20.3
Black	Total	49.6 ^¶	55.8	21.9	22.3
	Women	16.9	61.3	20.8	17.9
	Male	32.6	53.0	22.4	24.6
Hispanic	Total	20.6 ^¶	54.4	24.8	20.7
	Women	4.3	63.0	19.4	17.6
	Men	16.2	52.1	26.3	21.5
White	Total	27.2 ^¶	63.6	22.8	13.6
	Women	3.5	70.6	19.0	10.4
	Men	23.6	62.7	23.3	14.1

ART: antiretroviral therapy; SD: standard deviation; NRTI: nucleoside reverse transcriptase inhibitor.

Regimen selection is based on results of genotype analysis.

^†

CD4 count at time of seroconversion

^‡

Data from HIV Research Network [13].

^¶

Data do not sum to 100%, since 3% were identified as “Other” and excluded from the analysis.